NCT07078981 (ADHERE) is a clinical trial in Adhesive Small Bowel Obstruction, sponsored by Alessio Giordano.

Who is sponsoring NCT07078981?

NCT07078981 is sponsored by Alessio Giordano.

What condition does NCT07078981 study?

NCT07078981 studies Adhesive Small Bowel Obstruction, Postoperative Abdominal Adhesions, Bowel Obstruction, Abdominal Surgery Complications.

Is NCT07078981 still recruiting?

NCT07078981 is currently not yet recruiting. Last updated 22 July 2025.

Last reviewed 2025-07-22 · How we verify

NCT07078981: ADHERE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adhesion Prevention in ASBO Surgery Using 4DryField® PH

Not yet recruiting Last updated 22 July 2025

What this trial tests

trial in Adhesive Small Bowel Obstruction in 189 participants. Not yet recruiting.

Timeline

15 July 2025

Primary endpoint
15 July 2026

15 July 2027

Quick facts

Lead sponsor	Alessio Giordano
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	189
Start date	15 July 2025
Primary completion	15 July 2026
Estimated completion	15 July 2027

Conditions studied

Adhesive Small Bowel Obstruction — all drugs for Adhesive Small Bowel Obstruction →
Postoperative Abdominal Adhesions — all drugs for Postoperative Abdominal Adhesions →
Bowel Obstruction — all drugs for Bowel Obstruction →
Abdominal Surgery Complications — all drugs for Abdominal Surgery Complications →

Sponsor

Alessio Giordano

Who can join

18 and older, any sex, with Adhesive Small Bowel Obstruction or Postoperative Abdominal Adhesions. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Post-surgical adhesions occur in up to 90% of abdominal surgeries, often leading to complications like adhesive small bowel obstruction (ASBO) and chronic pain. They result from imbalanced healing processes influenced by growth factors, fibroblast activity, and genetic predispositions. While surgery can relieve ASBO, it frequently causes new adhesions, with recurrence rates up to 40%. Anti-adhesion barriers, such as the starch-based 4DryField® PH, form a temporary gel barrier to support healing. Though promising, its role in preventing ASBO recurrence is not well studied. This study evaluates whether intra-operative use of 4DryField® PH reduces ASBO recurrence over 12 months and compares perioperative outcomes in treated vs. untreated patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Adhesive Small Bowel Obstruction

Currently open trials in the same condition.

NCT06182319 — Optimizing Treatment of Adhesive Small Bowel Obstruction · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07078981 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alessio Giordano
Last refreshed: 22 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07078981.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing